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ABSTRACT 
 
OBJECTIVE: The objective of this selective Evidence Based Medicine (EBM) review is to 
determine whether or not Desvenlafaxine is effective in reducing daily hot flashes in 
postmenopausal females.  
 
STUDY DESIGN: Review of three primary randomized controlled trials (RCTs) published after 
the year 2000 in the English language. 
 
DATA SOURCES: Three double-blind, randomized controlled trials were found using PubMed 
and EBSCOhost Web. All trials selected compared treatment with Desvenlafaxine to a visually 
matched placebo.  
 
OUTCOMES MEASURED: Patients completed daily diary cards on which they recorded the 
number and severity of daily hot flashes from the screening period through the 12 weeks of 
therapy. Patients completed self-administered questionnaires at baseline and after 12 weeks of 
treatment: Profile of Mood States, Work Limitations, Menopause Symptoms Treatment 
Satisfaction, Sexual Functioning, EuroQuality of Life Visual Analog Scale, Greene Climacteric 
Scale (GCS). 
 
RESULTS: All three RCTs demonstrated a statistically significant reduction in the number of 
moderate to severe daily hot flashes in postmenopausal women receiving treatment with 
Desvenlafaxine compared to those receiving the placebo.  
 
CONCLUSION: The results of the RCTs evaluated suggest Desvenlafaxine is effective in 
reducing the daily number of moderate-severe hot flashes in postmenopausal women.  
 
KEY WORDS: Desvenlafaxine, hot flashes, vasomotor symptoms, menopause, serotonin-
norepinephrine reuptake inhibitor 
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INTRODUCTION  
 
Vasomotor symptoms, more commonly known as hot flashes, are transient periods of 
extreme warmth, flushing and sweating, most commonly affecting the trunk and face.1 
Subsequent chills, anxiety and heart palpitations often occur concomitantly with hot flashes.1 Hot 
flashes ordinarily begin during the transition to menopause, and according to several trajectory 
studies, are most bothersome during late perimenopause and early postmenopause.1  
Hot flashes are the most commonly reported menopausal symptom and affect as many as 
79% of postmenopausal females in the United States.1 Vasomotor symptoms are such a prevalent 
problem for women, and result in increased direct and indirect costs as well as increased 
healthcare utilization.2 In a study of more than 500,000 women, it was calculated that women 
with hot flashes incurred an additional $339,559,598 in direct health care costs per year and 
$27,668,410 in indirect costs.2 Women affected by hot flashes in the study population had 1.5 
million office visits over the one year period, representing an 82% increase in general outpatient 
visits, and a 121% increase in visits specifically for hot flashes as compared to control 
counterparts.2 
The mechanism of hot flashes is multifaceted and not entirely understood, but it is likely 
related to declining estrogen production from the ovaries during menopause.3 More noticeable 
oscillations in core body temperature result from a restricted thermoneutral zone in females 
undergoing the menopausal transition.3 Vasodilation and increased blood flow to the trunk and 
face are responsible for the initial flushing feeling that is often followed by profuse sweating.3 
Palpitations, anxiety, night sweats and consequent insomnia frequently accompany hot flashes.3 
There are several therapies currently available to treat vasomotor symptoms associated 
with menopause.  For quite some time, the mainstay of treatment was hormone replacement 
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therapy, consisting of estrogen, progestogen or a combination of the two.3 Nonhormonal 
pharmacological therapies include selective serotonin reuptake inhibitors (SSRIs), serotonin- 
norepinephrine reuptake inhibitors (SNRIs), Clonidine, and Gabapentin.3 An emphasis is also 
placed on nonpharmacologic therapies including behavioral changes, such as dressing in layers, 
setting a low room temperature and avoiding spicy foods and alcohol.3  Complementary and 
alternative treatments such as Black Cohosh, acupuncture and hypnosis are additionally being 
studied for the reduction of vasomotor symptoms. 3 
While hormone therapy remains the most effective method for treating hot flashes, the 
use of hormone therapy has significantly declined after results were released from the 2002 
Women’s Health Initiative (WHI). 4 The WHI highlighted several major risks associated with 
hormone therapy including breast cancer, pulmonary embolism, stroke and coronary heart 
disease, causing many to question whether the benefits outweighed the risks.4 Treatment with 
Desvenlafaxine, a serotonin norepinephrine reuptake inhibitor (SNRI), is being proposed because 
Desvenlafaxine has been shown to be an effective nonhormonal treatment alternative for hot 
flashes.5 
This review evaluates three double-blind, randomized, placebo-controlled trials 
comparing the efficacy of Desvenlafaxine, a SNRI, as an oral nonhormonal medication for 
reducing hot flashes in postmenopausal females. 
 
OBJECTIVE 
 
 The objective of this selective EBM review is to determine whether or not 
Desvenlafaxine is effective in reducing daily hot flashes in postmenopausal females.  
METHODS 
 
Three double-blind, placebo-controlled, RCTs that included healthy postmenopausal 
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females experiencing at least 50 moderate to severe hot flashes per week were chosen for 
analysis. All three trials compared the experimental group receiving 100mg of Desvenlafaxine to 
a control group receiving a visually matched placebo.  The outcome measured in all three studies 
was change from baseline in the average daily number of moderate to severe hot flashes after 12 
weeks. 6, 7,8 
A search using PubMed and EBSCOhost with the key words “Desvenlafaxine”, “hot 
flashes”, and “menopause” was used to find relevant studies published in English after the year 
2000. Articles chosen were published in peer-reviewed journals and were selected based on 
relevance to the clinical question and an emphasis on patient oriented outcomes.   
Inclusion criteria for all three trials selected for review consisted of healthy 
postmenopausal females experiencing at least 50 moderate to severe hot flashes per week. 
Menopause was defined as at least 12 months of spontaneous amenorrhea, 6 months of 
spontaneous amenorrhea with follicle-stimulating hormone (FSH) levels greater than 40mIU/mL, 
or 6 weeks postsurgical bilateral oophorectomy.6, 7,8 Speroff et al. and Archer et al. included 
women with a BMI less than or equal to 40 kg/m2.6, 7 Pinkerton et al. included women at least 45 
years old with a BMI less than or equal to 34 kg/m2 and additionally defined menopause by a 
hysterectomy with FSH level greater than 40 mIU/mL.8 
Exclusion criterion was similar for all three studies used in this review.  The exclusion 
criteria included recent treatment for vasomotor symptoms with either hormone therapy, 
psychoactive medications or investigational drugs, known hypersensitivity to Venlafaxine, or 
certain comorbid medical conditions.6, 7,8 Table 1 highlights the specific exclusion criteria.  
Statistics based on dichotomous data were reported using change from baseline, analysis 
of covariance (ANCOVA), and p-values.  Control event rate (CER) and experimental event rate 
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(EER) were used to calculate absolute benefit increase (ABI) and absolute risk increase (ARI). 
The number needed to treat (NNT) was calculated from the ABI; the ARI was used to determine 
number needed to harm (NNH).  
Table 1: Demographics & Characteristics of Included Studies  
Study Type 
 
# Pts Age 
(years) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions  
Speroff et 
al., 2008 
(6) 
Double 
Blind 
RCT 
707 39-78 Healthy 
postmenopausal 
women with a 
BMI ≤ 40, ≥ 50 
moderate-severe 
hot flashes/week; 
Menopause 
defined as ≥12 
months of 
spontaneous 
amenorrhea or ≥ 
6 months of 
spontaneous 
amenorrhea with 
serum FSH levels 
> 40 mlU/mL or 
≥ 6 wks. 
postsurgical 
bilateral 
oophorectomy 
 
Hypersensitivity to 
Venlafaxine, use of 
hormone therapy 
within 4 wks- 6mo. 
of screening, 
psychoactive drug 
use within 4 weeks 
of screening, 
investigational 
drug use within 30 
days of screening, 
history of seizure 
disorder, MI 
(within 6 months), 
malignancy or 
treatment for 
malignancy (within 
2 years), narrow-
angle glaucoma or 
current raised 
intraocular 
pressure, hepatic/ 
renal disease, 
presence of major 
depressive, bipolar, 
psychotic, or 
generalized anxiety 
disorder, untreated 
malabsorption 
disorder; persistent 
elevated blood 
pressure, other 
clinically 
important 
abnormalities at 
screening 
97 (29= 
placebo
, 68= 
100mg 
Desvenl
afaxine) 
Desvenlafaxine 
100 mg orally 
once daily  
Archer et 
al., 2009 
(7) 
Double 
Blind 
RCT 
567 53.5 ± 
5.20 
years  
106 
(42= 
placebo
, 64= 
100mg 
Desvenl
afaxine) 
Desvenlafaxine 
100 mg orally 
once daily 
Pinkerton 
et al., 
2013 (8) 
Double 
Blind 
RCT 
365 46-71 Same as above 
inclusion criteria. 
Plus: Age ≥ 45 
y/o, BMI ≤ 34.0; 
GCS total score 
of ≥ 12 & a GCS 
hot flash Score of 
≥ 2; Menopause 
defined as a hysterectomy	  with	  serum	  FSH	  >	  40	  mIU/mL.	  	  
 
 
67 (30= 
placebo
, 37 = 
100mg 
Desvenl
afaxine)  
Desvenlafaxine 
100 mg orally 
once daily 
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OUTCOMES MEASURED 
 
Each of the RCTs used in this systematic review evaluated patient oriented evidence that 
matters (POEMs) and assessed the efficacy of Desvenlafaxine in reducing the frequency of daily 
hot flashes. Patients in each trial completed daily diary cards on which they recorded the number 
and severity of daily hot flashes from the screening period through the 12 weeks of therapy.  
Mild hot flashes were characterized by a fleeting warm sensation without perspiration or 
disruption to activity; moderate hot flashes were defined as a warm sensation with sweating 
without a disruption to activity; severe hot flashes disrupted activity with a hot sensation and 
sweating.6 The average daily number of moderate to severe hot flashes was calculated as the sum 
of moderate to severe hot flashes on each day divided by the days in the week with data.7, 8 
Patients completed self-administered questionnaires at baseline and after 12 weeks of treatment.  
Speroff et al. used the Profile of Mood States (POMS), Work Limitations (WLQ), Menopause 
Symptoms Treatment Satisfaction, Sexual Functioning and EuroQuality of Life Visual Analog 
Scale to monitor improvement throughout the treatment phase.6 Archer et al. utilized the POMS, 
WLQ and Greene Climacteric Scale (GCS) 7 
RESULTS 
  
 Dichotomous data was used in all three trials and was used to calculate both the efficacy 
and safety of the interventions.  Each of the trials evaluated the efficacy of 100mg of 
Desvenlafaxine daily for 12 weeks in reducing the average daily number of moderate to severe 
hot flashes compared to a placebo. There were no statistically significant demographic 
differences noted between the treatment and control groups at baseline. Results were based on 
daily diaries the patients kept, which noted the frequency and severity of daily hot flashes. 
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 The RCT conducted by Speroff et al. showed a statistically significant decrease from 
baseline in the average number of daily hot flashes for the 100mg Desvenlafaxine group 
compared to placebo after 12 weeks (p =. 005).6 Treatment with Desvenlafaxine yielded a 64% 
decrease from baseline whereas the treatment with placebo only showed a 51% decrease.6 
Likewise, the RCT conducted by Archer et al. showed a similarly significant decrease from 
baseline in the average number of hot flashes after 12 weeks of therapy; a 60% reduction was 
noted in the treatment group compared to a 47% reduction with the placebo group (p ≤.002). 7 
Finally, the RCT by Pinkerton et al. showed similar findings, with a 62% reduction in daily hot 
flashes for the Desvenlafaxine group in contrast with a 38% decrease for the placebo group (p ≤ 
.001) (Table 2) 
Table 2: Percentage Decrease from Baseline in Average Daily Number of Hot Flashes  
 
  
 
 
 Additionally in Speroff et al., the Desvenlafaxine group had 50% of women achieve at 
least a 75% reduction from baseline in average daily number of hot flashes compared to 29% in 
the placebo group after 12 weeks of therapy (p = .003). 6 Archer et al. demonstrated that 41.4% 
of patients treated with Desvenlafaxine achieved at least a 75% reduction in the number of hot 
flashes compared to the 26.4% treated with placebo over the 12-week period (p =. 004). 7 
Pinkerton et al. showed a significantly larger percent of women in the Desvenlafaxine group 
achieving a minimal clinically important difference when compared to the placebo group, 63.6% 
compared to 41.4% respectively (p < .001).  The minimal clinically important difference was 
determined to be a reduction of 5.35 hot flashes from baseline.8 Treatment effects from the 3 
STUDY Desvenlafaxine 100 mg Placebo 
Speroff et al.6 64% 51% 
Archer et al.7 60% 47% 
Pinkerton et al.8 62% 38% 
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RCTs are presented in Table 3. The control event rate (CER) and experimental event rate (EER) 
were used to calculate the relative benefit increase (RBI) and absolute benefit increase (ABI). 
The ABI was subsequently used to determine the numbers needed to treat (NNT).  The NNT 
represents the number of patients that need to be treated with 100mg of Desvenlafaxine for one 
additional patient to benefit from the intervention compared to a placebo.  The benefit in this 
case is a reduction in average daily number of hot flashes.  
 
Table 3: Treatment Effects of Desvenlafaxine   
STUDY CER  EER  RBI ABI  NNT  
Speroff et al.6 0.29 0.5 0.72 0.21 5 
Archer et al.7 0.264 0.414 0.57 0.15 7 
Pinkerton et 
al.8 
0.414 0.636 0.54 0.222 5 
 
 Furthermore, CER and EER were used to calculate the relative risk increase (RRI) and 
absolute risk increase (ARI).  The equation 1/ARI was used to determine the numbers needed to 
harm (NNH). Nausea was the most commonly reported adverse event in all three RCTs for the 
Desvenlafaxine group compared to the placebo group, and therefore data for nausea was used to 
calculate NNH.6, 7,8 NNH represents the number of patients treated with Desvenlafaxine 100mg 
that would result in one more patient experiencing an adverse event, in this instance nausea, 
when compared to placebo.  All three RCTs consistently showed a higher incidence of nausea in 
the Desvenlafaxine 100mg group compared to the placebo group.  38.7% of the Desvenlafaxine 
100mg group in Speroff et al. reported nausea compared to 6.5% in the placebo group (95% 
Confidence Interval 2.62 to 14.41). 6 Archer et al. confirmed similar findings with 45.1% of the 
100mg Desvenlafaxine group reporting nausea compared to 8.3% of the placebo group (p < 
.001). 7 Finally, Pinkerton et al. paralleled the previous two studies with 16.5% of the 
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Desvenlafaxine 100mg patients reporting nausea compared with only 6.3% of the placebo 
patients (p = .002). 8 Calculations for harm for all three RCTs are summarized in Table 4.  
 
Table 4: Calculations for Harm (Nausea) 
STUDY CER EER RRI ARI NNH 
Speroff et 
al.6 
0.065 0.387 4.95 0.322 3 
Archer et 
al.7 
0.083 0.451 4.43 0.368 3 
Pinkerton et 
al.8 
0.063 0.165 1.62 0.102 10 
 
 Participants in the Desvenlafaxine groups reported more treatment related adverse effects 
than the placebo group in all three RCTs.  In Speroff et al., 87% of women in the placebo group 
reported adverse effects compared to 94% of women treated with 100mg of Desvenlafaxine.6 
The differences between groups were only noteworthy during the first week of treatment and 
after that point there were no statistically significant differences between groups in the incidence 
of new adverse effects.6 Discontinuations due to adverse effects did not differ between the 
placebo group and the 100mg Desvenlafaxine group.6 Nausea, dizziness and headache were the 
most frequently reported discontinuation complaints.6 Archer et all. paralleled the results found 
by Speroff et all. with 95.1% of the treatment group reporting at least one adverse effect 
compared to 88.3% of the placebo group.7 Commonly reported adverse effects of Desvenlafaxine 
patients that resulted in discontinuation were nausea and dizziness. 7 Although there were more 
adverse event related discontinuations from the Desvenlafaxine group than the placebo group 
during the first week of therapy, there were no significant differences in reported adverse effects 
between the groups after week one of therapy.7 Speroff et al. and Archer et al. both reported 90% 
compliance rates with therapy for both the Desvenlafaxine group and placebo group after the 
first week of therapy. Compliance was determined by returned pill counts and daily diary 
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information; compliance with treatment was defined as taking at least 80% of dispensed doses.6, 7 
Pinkerton et al. reported 10% of Desvenlafaxine patients discontinuing due to adverse effects 
compared to only 3.7% of placebo patients (p =. 016).8  A similar pattern was observed in the 
study by Pinkerton et al.; 39.5% of Desvenlafaxine patients conveyed treatment emergent 
adverse effects during week one in comparison to 16.8% of placebo patients (p <.001), however, 
after the first week no significantly noticeable differences existed between the two groups in 
regards to treatment emergent adverse effects.8 The most commonly reported adverse effects 
were nausea, constipation, dry mouth, diarrhea, fatigue and somnolence.8 
  
DISCUSSION 
 
 All three RCTs used in this review concluded that 100mg of Desvenlafaxine daily 
significantly reduced the number of hot flashes in postmenopausal women compared with 
placebo.  Although hormone replacement therapy still remains the most effective treatment for 
menopausal vasomotor symptoms, Desvenlafaxine proved to be a successful nonhormonal 
alternative, demonstrating both clinically and statistically significant improvements in hot flashes 
related to menopause. Desvenlafaxine is currently marketed primarily for its use as an 
antidepressant medication in major depressive disorder (MDD). 9 The use of Desvenlafaxine in 
the treatment of menopausal vasomotor symptoms is currently an off-label indication.9 Although 
proven to be an effective nonhormonal treatment alternative for menopausal hot flashes, there are 
several contraindications to using Desvenlafaxine.  Desvenlafaxine should be avoided in patients 
with a known hypersensitivity to Desvenlafaxine, Venlafaxine, or any other formulary 
component.  Moreover, Desvenlafaxine should be avoided in patients who recently used a 
monoamine oxidase inhibitor (MAOI) for the treatment of a psychiatric condition because of the 
major risk of serotonin syndrome.9 It is important to note that Desvenlafaxine should be used 
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with caution in elderly patients because of the risk of hyponatremia and orthostatic hypotension.9 
Manufacturers of Desvenlafaxine recommend tapering the drug slowly over several weeks upon 
discontinuation of therapy to minimize side effects.  Desvenlafaxine is a prescription medication 
that is available as a generic medication in the United States. Most insurance companies cover 
Desvenlafaxine, however without insurance this medication can cost anywhere from $174.14 to 
$399.00 for a 30 day supply of the 100mg tablets.9  
 Limitations in the RCTs used in this review include a lack of diversity in the subject 
population and lack of dose titration and tapering protocols at the initiation and discontinuation 
of treatment. The majority of subject participants (> 80%) were Caucasian, so the 
generalizability of the results to postmenopausal women of other races is limited.  The lack of 
dose titration and tapering is likely responsible for the majority of the adverse events and 
discontinuation symptoms reported in all three RCTs.  These limitations prompt areas of future 
research to improve both the generalizability and tolerability of Desvenlafaxine as an 
intervention for vasomotor symptoms in menopause. 
 
CONCLUSION 
 
 Based on the analysis of the three RCTs, this selective Evidence-Based Medicine review 
concludes that Desvenlafaxine is an effective nonhormonal treatment for moderate to severe hot 
flashes associated with menopause.  A statistically and clinically significant reduction in the 
frequency of moderate to severe hot flashes was observed following treatment with 
Desvenlafaxine when compared with a visually matched placebo.  The efficacy of 
Desvenlafaxine was comparable to other nonhormonal centrally acting medications. 
Desvenlafaxine was found to be generally safe and well tolerated, consistent with that of other 
drugs in the serotonin-norepinephrine reuptake inhibitor class.
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